Prying clinical-stage assets—even ones given up for dead—out of the steely grasps of pharmaceutical companies remains a tedious and difficult proposition; it’s hardly ever the smoothest of negotiations. Identifying that special project—the one that inspires the perfect blend of biotech excitement and pharmaco-nonchalance—is only the first hurdle. Many biotech attempts to out-license pharmaceutical candidates turn out to be fruitless: the pharma changes its mind, the biotech can’t come up with a reasonable strategy for the compound, or a fair deal can’t be worked out.
Pharma’s reluctance is well documented, which makes those successful deals all the more noteworthy. Last year START-UP flagged a handful...







